No Q2 call yet for a Colorado medtech; San Diego biotech collabs with MD Anderson – Endpoints News

A Lit­tle­ton, CO, sleep ap­nea medtech was sup­posed to hold its Q2 earn­ings call on Aug. 15, then Aug. 22 and now maybe not for weeks.
It could take “sev­er­al weeks” be­fore Vivos Ther­a­peu­tics re­solves is­sues with a “tech­ni­cal reeval­u­a­tion of our rev­enue recog­ni­tion pol­i­cy,” the com­pa­ny said Mon­day af­ter the clos­ing bell. Vivos CEO Kirk Hunts­man said the de­lay is “un­re­lat­ed to the over­all health” of the com­pa­ny.
“We were re­cent­ly ad­vised by our in­de­pen­dent reg­is­tered pub­lic ac­coun­tants about a po­ten­tial need to reeval­u­ate how and when we rec­og­nize en­roll­ment fees charged to new Vivos In­te­grat­ed Providers (VIPs) and the re­lat­ed per­for­mance oblig­a­tions that are in­clud­ed in VIP en­roll­ments as rev­enue un­der ASC Top­ic 606,” the com­pa­ny said in its Mon­day state­ment.
The com­pa­ny is “hope­ful” that the re­sult of the au­di­tors’ and in­de­pen­dent con­sul­tants’ work will not lead to any ma­te­r­i­al im­pact on “cur­rent or pri­or re­sults of op­er­a­tions.”
Hunts­man said Vivos thinks it has moved be­yond the worst days of Covid-19’s im­pact and can keep the lights on un­til ear­ly 2024.
Eras­ca strength­ens its bond with MD An­der­son in­ves­ti­ga­tors 
A San Diego-based pre­ci­sion on­col­o­gy biotech will team up with MD An­der­son Can­cer Cen­ter to re­search and de­vel­op mul­ti­ple can­cer drugs.
Eras­ca and the famed Texas re­search cen­ter will work on monother­a­pies and po­ten­tial com­bi­na­tion ther­a­pies that tar­get the RAS/MAPK path­way, the duo an­nounced Tues­day morn­ing.
The first part of the five-year tie-up is geared to­ward Eras­ca’s ERK1/2 in­hibitor, dubbed ERAS-007, and the SHP2 in­hibitor ERAS-601.
That first as­set is al­ready in mul­ti­ple clin­i­cal tri­als across non-small cell lung can­cer and gas­troin­testi­nal ma­lig­nan­cies. The oth­er drug is in var­i­ous clin­i­cal stud­ies of pa­tients with col­orec­tal can­cer, NSCLC, and HPV-neg­a­tive head and neck squa­mous cell car­ci­no­ma.
MD An­der­son in­ves­ti­ga­tors Scott Kopetz and David Hong are al­ready fa­mil­iar with the biotech, as they are in­volved in some of Eras­ca’s clin­i­cal stud­ies.
Per the agree­ment, the pair will team up on pre­clin­i­cal and clin­i­cal stud­ies across NSCLC, GI ma­lig­nan­cies and “ad­di­tion­al mu­tu­al­ly agreed-up­on in­di­ca­tions.”